Drawing for INTRACEUTICS

USPTO serial 87245461

INTRACEUTICS

Reviewed by CopyMark Law Group

Status 601
Filing date
Status date
Registration date
—
Examiner
MARTIN, CHRISTINE C
Law office
TMEG LAW OFFICE 104 - EXAMINING ATTORNEY ASSIGNED

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with INTRACEUTICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Michael J. Leonard

MICHAEL J. LEONARD FOX ROTHSCHILD LLP997 LENOX DRIVE, BLDG. 3LAWRENCEVILLE, NJ 08648-2311UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations and substances for the prevention and treatment of menopause, sexual dysfunction, vaginal atrophy, decreased libido, gynaecological disorders affecting menstruation, premenstrual syndrome, sterility, menstrual syndromes, dysmenorrhea, infertility, genital tract infections, pelvic inflammatory diseases, endometriosis, vaginal discomfort due to menopausal atrophic changes, anatomical abnormalities; pharmaceutical preparations and substances for the prevention and treatment of menopausal problems, neoplasia, breast neoplasm, breast cancer, mastopathy, mastodynia, breast pain; pharmaceutical preparations and substances for the prevention and treatment of the endocrine system; pharmaceutical preparations and substances for the prevention and treatment of oily skin, acne, male baldness; pharmaceutical preparations and substances for the prevention and treatment of prostate cancer and benign prostate enlargement; pharmaceutical preparations and substances for the prevention and treatment of obesity, high cholesterol, diabetes, loss of muscle mass and strength, bone lossACTIVE—
035Wholesale distributorship of pharmaceuticals for othersACTIVE—
040Custom manufacture of pharmaceutical products to the order and specification of othersACTIVE—
041Pharmaceutical educational services and patient educational services, namely, providing classes, workshops and seminars in the fields of treatment and prevention of cancer and endocrine-related disorders and diseasesACTIVE—
042Research and development in the field of pharmaceuticals; conducting early evaluations in the field of new pharmaceuticals; medical laboratory services; laboratory research in the fields of treatment and prevention of cancer and endocrine-related disorders and diseasesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 3, 2017MAB1ABANDONMENT NOTICE MAILED - EXPRESS ABANDONMENT—
Jul 3, 2017ABN1ABANDONMENT - EXPRESS MAILED—
Jun 30, 2017EXARTEAS EXPRESS ABANDONMENT RECEIVED—
Mar 6, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 6, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 6, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 28, 2017DOCKASSIGNED TO EXAMINER—
Nov 30, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 25, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance